

A New Therapeutic Approach to Chronic Wound Healing

Chronic wounds are a global health crisis; millions remain unhealed despite treatment.

Current therapies manage wounds, but rarely restart the biology of repair.

SolasCure is developing Aurase Wound Gel, a Phase II biologic designed to both debride and actively drive healing.

Selected for the Innovate UK & TMC Innovation Accelerator Program, in partnership with Texas Medical Center, in 2024

Awarded the Biomedical Catalyst Grant by Innovate UK, the UK's innovation agency in 2024

Awarded EIC Accelerator Grant by the European Innovation Council in 2023

Selected as a 2023 Life Sciences Innovator by UK Department for Business and Trade

1st place in the Biotech Category at EIT Health Catapult (European Institute of Innovation & Technology) in 2022

Winner of the 2019 URGO Mentorship Program
Industry Recognition

Latest News

Aurase Wound Gel combines continuous enzymatic wound bed preparation with activation of endogenous repair pathways, shifting treatment from maintenance toward therapeutic repair.



_edited.jpg)